[Consensus: Rational approach towards the patient with cancer, fever and neutropenia].
The severity and duration of post chemotherapy neutropenia were recognized during the 1960s as main predisposing factors for infections in cancer patients. At the beginning of the 70's a standard management approach for all febrile neutropenia (FN) episodes was proposed, based on hospitalization and intravenous empirical broad spectrum antibiotic therapy. Widespread use of this approach resulted in a significant reduction in mortality attributable to bacterial infections. During the last 10 to 15 years, reappraisal of this standard approach has been done by several research groups who question the benefit of treating all FN patients similarly without taking in to consideration differences in severity of the FN episodes. This reappraisal has led during the 1990s to the development of the concept of high and low risk FN episodes that has been the base for the adoption of selective therapies based on the risk categorization of the individual patient. The Chilean Infectious Diseases Society called upon two government National Programs responsible for the appropriate distribution of chemotherapeutic drugs to all pediatric and adults cancer patients within the public health system, and upon the Chilean Hematology Society for the development of a Consensus on Diagnosis, Treatment and Prevention of Infections during FN Episodes in Cancer patients. The need for this Consensus is based on two main aspects: the new approaches proposed during the past year for management of these episodes, and the increasing population of cancer patients receiving improved chemotherapeutic agents that has increased there survival possibilities as well as there possibility to suffer a FN episode. The topics discussed in this document are based on an updated systematic and analytic review of the medical literature including epidemiology, laboratory diagnostics, risk categorization, treatment and prophylaxis. National data was included when available in order to provide the healthcare personnel that take care of these patients with best evidence based recommendations adjusted to the Chilean reality.
Santolaya
María Elena
ME
Sociedad Chilena de Infectología.
Rabagliati
Ricardo
R
Bidart
Teresa
T
Payá
Ernesto
E
Guzmán
Ana M
AM
Morales
Ricardo
R
Braun
Stephanie
S
Bronfman
Lucía
L
Ferrés
Marcela
M
Flores
Claudio
C
García
Patricia
P
Letelier
Luz M
LM
Puga
Bárbara
B
Salgado
Carmen
C
Thompson
Luis
L
Tordecilla
Juan
J
Zubieta
Marcela
M
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001424:Bacterial Infections / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D005334:Fever / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D009503:Neutropenia / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D009894:Opportunistic Infections / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D018570:Risk Assessment
D000970:Antineoplastic Agents